After a whipsaw year for Big Pharma stocks in 2015, there are some compelling value opportunities out there.
By Lawrence Meyers | Dec 2, 2015
Do the current Dow 30 stocks really represent the economy as broadly as possible?
By Bob Ciura | Oct 13, 2015
Despite missing revenue projections by $340 million, Johnson & Johnson remains a quality blue chip stock that dividend investors can count on.
By Bob Ciura | Sep 3, 2015
After the recent market plunge, long-term investors should consider these three Dow dividend stocks to buy now on the cheap.
By Marshall Hargrave | Jun 5, 2015
Last week we found out that gross domestic product contracted at an annual rate of 0.7%. That’s well below the 0.2% fall that economists were expecting.
By Jim Nelson | May 8, 2015
Pay attention to these, the most attractive among dividend stocks on the Dow. Now is the time to jump in.
By Jay Taylor | Apr 10, 2015
Alcoa led off earnings season this week with a report that sent its stock lower by 4%. Let’s hope that the rest of the market doesn’t follow Alcoa’s lead.
By Lawrence Meyers | Feb 18, 2015
You may be surprised at what turned up among the most undervalued dividend aristocrats. I was.